The FDA has issued a new warning for the type 2 diabetes medicine canagliflozin (offered under the brand names Invokana, Invokamet, and Invokamet XR). Two large clinical trials have indicated the drug carries an increased risk of leg and foot amputations. The FDA advises patients taking canagliflozin to immediately notify their doctor if they experience new pain or tenderness, sores or ulcers, or infections in legs or feet. Patients should not stop taking the medicine without first talking to their health care professional. Read more